134 related articles for article (PubMed ID: 35979387)
1. PARP1 inhibition elicits immune responses against non-small cell lung cancer.
Juncheng P; Lafarge A; Kroemer G; Castedo M
Oncoimmunology; 2022; 11(1):2111915. PubMed ID: 35979387
[TBL] [Abstract][Full Text] [Related]
2. Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancer.
Juncheng P; Joseph A; Lafarge A; Martins I; Obrist F; Pol J; Saavedra E; Li S; Sauvat A; Cerrato G; Lévesque S; Leduc M; Kepp O; Durand S; Aprahamian F; Nirmalathansan N; Michels J; Kroemer G; Castedo M
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35772809
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
[TBL] [Abstract][Full Text] [Related]
4. Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer.
Michels J; Adam J; Goubar A; Obrist F; Damotte D; Robin A; Alifano M; Vitale I; Olaussen KA; Girard P; Cremer I; Castedo M; Soria JC; Kroemer G
Ann Oncol; 2015 Dec; 26(12):2470-7. PubMed ID: 26387143
[TBL] [Abstract][Full Text] [Related]
5. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
6. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer: A Review.
Guo MZ; Marrone KA; Spira A; Scott SC
Cancer J; 2021 Nov-Dec 01; 27(6):476-481. PubMed ID: 34904810
[TBL] [Abstract][Full Text] [Related]
8. Differential and Concordant Roles for Poly(ADP-Ribose) Polymerase 1 and Poly(ADP-Ribose) in Regulating WRN and RECQL5 Activities.
Khadka P; Hsu JK; Veith S; Tadokoro T; Shamanna RA; Mangerich A; Croteau DL; Bohr VA
Mol Cell Biol; 2015 Dec; 35(23):3974-89. PubMed ID: 26391948
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin resistance associated with PARP hyperactivation.
Michels J; Vitale I; Galluzzi L; Adam J; Olaussen KA; Kepp O; Senovilla L; Talhaoui I; Guegan J; Enot DP; Talbot M; Robin A; Girard P; Oréar C; Lissa D; Sukkurwala AQ; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Dessen P; Saparbaev M; Soria JC; Castedo M; Kroemer G
Cancer Res; 2013 Apr; 73(7):2271-80. PubMed ID: 23554447
[TBL] [Abstract][Full Text] [Related]
10. PARP1 inhibition alleviates injury in ARH3-deficient mice and human cells.
Mashimo M; Bu X; Aoyama K; Kato J; Ishiwata-Endo H; Stevens LA; Kasamatsu A; Wolfe LA; Toro C; Adams D; Markello T; Gahl WA; Moss J
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830864
[TBL] [Abstract][Full Text] [Related]
11. The activity and inhibition of poly(ADP-ribose) polymerase-1 in equine peripheral blood mononuclear cells in vitro.
Douglas HF; Southwood LL; Meyer-Ficca ML; Hart SK; Meyer RG
J Vet Emerg Crit Care (San Antonio); 2015; 25(4):528-37. PubMed ID: 26040949
[TBL] [Abstract][Full Text] [Related]
12. PARP mediated DNA damage response, genomic stability and immune responses.
Zong C; Zhu T; He J; Huang R; Jia R; Shen J
Int J Cancer; 2022 Jun; 150(11):1745-1759. PubMed ID: 34952967
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
[TBL] [Abstract][Full Text] [Related]
15. The impact of cycleanine in cancer research: a computational study.
Nwaefulu ON; Al-Shar'i NA; Owolabi JO; Sagineedu SR; Woei LC; Wai LK; Islam MK; Jayanthi S; Stanslas J
J Mol Model; 2022 Oct; 28(11):340. PubMed ID: 36194315
[TBL] [Abstract][Full Text] [Related]
16. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
18. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
19. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
20. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV
Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
